South San Francisco, United States
Second Genome Inc. is a pioneering player in the biotech sector, focusing on the development of precision therapies derived from microbiome science. Since its founding in 2009, Second Genome has demonstrated its expertise by advancing a pipeline of novel therapies geared towards addressing serious diseases.
The company’s innovative strength lies in its unique discovery platform which has not only propelled it to the forefront of healthcare but also enabled breakthroughs across industries such as nutrition and agriculture. This versatility has established Second Genome as a global leader in transforming cutting-edge science into practical applications.
Headquartered in the United States, Second Genome fosters a culture of excellence and collaboration, making them a preferred partner for leading corporations and academic institutions. As they continue to engage in strategic partnerships, their last reported investment was a grant on 03 October 2017. Investors seeking opportunities in transformative biotech innovations might find Second Genome an intriguing prospect due to its pioneering approach and commitment to advancing human health.
